Zymedyne therapeutics

Chronic pain is one of the most serious health challenges that faces society today and current therapies are not universally effective and often have detrimental adverse effects, such as weight gain, respiratory depression and addiction. As a result, many patients are left with unmanaged chronic pain and new approaches are required.

Zymedyne was founded in 2020 by Drs. Gerald Zamponi and Chris Bladen (University of Calgary) and aims to develop safer and more effective treatments for chronic inflammatory and neuropathic pain by targeting Cav3.2 T-type calcium channels that are known to be crucial in pain signaling. Unlike opioids, our technology aims to achieve pain relief without the detrimental adverse effects that plague current users of chronic pain medications.